参麦注射液联合化疗治疗非小细胞肺癌的Meta分析  

Meta-analysis on treatment of non-small cell lung cancer with Shenmai injection in combination with chemotherapy

作　　者：彭婉 王建[1] 马骁[1] 陈念[1] 马荣 谢倩[1] 董泰玮 高思佳 敬勇[1] 李敏[1] PENG Wan;WANG Jian;MA Xiao;CHENNian;MA Rong;XIE Qian;DONG Tai-wei;GAO Si-jia;JING Yong;Li Min(School of Pharmacy,Chengdu University of Traditional Chinese Medicine/Key Laboratory of Standardization for Chinese Herbal Medicine,Ministry of Education/National Key Laboratory Breeding Base of Systematic Research,Development and Utilization of Chinese Medicine Resources,Chengdu 611137,Sichuan)

机构地区：[1]成都中医药大学药学院中药材标准化教育部重点实验室四川省中药资源系统研究与开发利用重点实验室--省部共建国家重点实验室培育基地,四川成都611137

出　　处：《中药与临床》2018年第3期51-56,63,共7页Pharmacy and Clinics of Chinese Materia Medica

基　　金：国家中药标准化行动项目"川贝母;半夏等7种中药饮片标准化建设"(ZYBZH-Y-SC-40);四川省科技厅科技支撑项目"麦冬整合式产业链综合开发研究"(2015SZ0033);四川省科技厅创新团队计划(2017TD0001);国家基础科学人才培养基金(J1310034);四川省中医药产业创新团队项目(2017C003)"四川省中医药产业创新团队专项--麦冬大健康产品开发"

摘　　要：目的:系统评价参麦注射液联合化疗治疗非小细胞肺癌的有效性。方法:检索各数据库自建库起至2017年10月关于参麦注射液联合化疗治疗非小细胞肺癌的临床随机对照文献,选择符合纳入标准的文献,采用Review Manager5.3软件进行系统评价。结果:本研究共纳入了26篇符合要求的文献,总样本量1808例。Meta分析结果显示,联合用药治疗与单独化疗相比能显著提高近期疗效[OR:1.44,95%CI,(1.18,1.76);P=0.003];通过比较联合用药治疗与单独化疗治疗的中医症状评分,发现联合用药治疗可显著提高中医症状评分[MD:-5.01,95%CI,(-8.93,-1.09);P=0.01];同时,联合用药治疗与单独化疗相比可显著提高卡氏评分的增加率[OR:3.18,95%CI,(2.42,4.19);P<0.00001]。此外,以CD3,CD4,CD8,CD4/CD8为代表的T细胞亚群水平结果提示,联合用药治疗显著优于单独化疗治疗(CD3[MD:8.96,95%CI,(5.27,12.66);P<0.00001];CD4[MD:9.29,95%CI,(2.47,16.11);P=0.008];CD8[MD:-8.43,95%CI,(-10.74,-6.12);P<0.00001];CD4/CD8([MD:0.72,95%CI,(0.15,1.29);P=0.01])。结论:本研究结果显示参麦注射液联合化疗方案与单纯化疗方案相比,可以显著增加疾病控制率,并提高患者的生活质量。Objective:To investigate the efficacy of Shenmai injection in combination with chemotherapy in treating nonsmall cell lung cancer(NSCLC).Method:Cochrane Library,Pub Med,Medline,CNKI,VIP and WANFANG DATA were screened.The retrieval time was from the establishment time of each database to Oct.2017.Randomized controlled trials(RCTs) of Shenmai injection in combination with chemotherapy were included and a Meta-analysis was carried out by Rev Man 5.3 software.Result:26 RCTs involving 1808 patients entered the inclusion criteria.The meta-analysis showed that compared with pure application of chemotherapy,Shenmai injectionin combination with chemotherapy can enhance the short-term curative effect [OR :1.44,95%CI,(1.18,1.76);P=0.003],improve the quality of life [OR :3.18,95%CI,(2.42,4.19);P < 0.00001],increase the TCM symptom score[MD :-5.01,95%CI,(-8.93,-1.09);P=0.01] and strengthen the immune:CD3 [MD:8.96,95%CI,(5.27,12.66);P< 0.00001 ];CD4:[MD:9.29,95%CI,(2.47,16.11);P =0.008];CD8:[MD:-8.43,95%CI,(-10.74,-6.12);P<0.00001];CD4/CD8:[MD:0.72,95%CI,(0.15,1.29);P= 0.01].Conclusion:Shenmai injection in combination with chemotherapy can not only enhance the short-term curative effect,but also improve the quality of life,and strengthen the immune.

关 键 词：参麦注射液 化学药物疗法 非小细胞肺癌 META分析 

分 类 号：R287[医药卫生—中药学]